Alliance to Develop Optical Imaging Products

(IDSI, Fort Lauderdale, FL, USA) and the Rumbaugh-Goodwin Institute for Cancer Research, Inc. (Plantation, FL, USA).

IDSI, which has developed a breast imaging product, is now developing a new line of products based on the company's optical computed tomography (CT) and fluorescent imaging technologies, called Laser Imaging for Lab Animals (LILA). The first model is a miniature optical CT scanner for imaging green fluorescent protein, derived from the DNA of jellyfish. The Rumbaugh-Goodwin Institute has expertise in optical imaging for determining the efficacy of new anticancer treatments and spontaneously metastasizing models of human breast cancer. The institute's main goal is to develop cancer therapies targeting tumors, with minimal cellular damage and toxicity for the patient.

"With this agreement, IDSI is addressing a new market, targeting pharmaceutical developers and researchers who monitor cancer growth,” noted Linda Grable, CEO of IDSI. "It is exciting and beneficial to be adding a new product line to complement our breast imaging product.”






Related Links:
IDSI
Rumbaugh